Organon Reports Soft Q4 2025 Results, Biosimilars Grow

An update from Organon ( (OGN) ) is now available.

Organon (NYSE: OGN), based in Jersey City, N.J., operates in the pharmaceuticals sector with a portfolio spanning women’s health, biosimilars and established brands. Key products include contraceptive implant Nexplanon, fertility treatments, respiratory drugs such as Singulair, migraine therapy Emgality, dermatology drug Vtama and a growing biosimilars franchise, positioning the company across both specialty and mature therapeutics markets.

The company reported its fourth-quarter and full-year 2025 results on February 12, 2026, with annual revenue of $6.2 billion, down 3% year on year, and full-year adjusted EBITDA of $1.91 billion, implying a 30.7% margin. Quarterly revenue fell 5% to $1.507 billion, as women’s health, notably Nexplanon, declined on U.S. wholesaler practice changes, policy-driven access limits and softer demand, while biosimilars grew 11% on strong Hadlima and new denosumab and tocilizumab assets.

Established brands slipped modestly as contributions from Emgality, Vtama and Arcoxia were offset by pricing and volume pressure in respiratory drugs, particularly amid revised guidelines that deprioritize montelukast globally. Profitability weakened, with Q4 gross margin dropping to 49.2% from 56.3% and a net loss of $205 million versus prior-year profit, driven by one-time manufacturing optimization costs, unfavorable pricing, FX and product mix, even as management emphasized balance sheet repair and a 2026 outlook broadly in line with 2025 performance.

The most recent analyst rating on (OGN) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Organon stock, see the OGN Stock Forecast page.

Spark’s Take on OGN Stock

According to Spark, TipRanks’ AI Analyst, OGN is a Neutral.

The score is held back primarily by high leverage and declining profitability, plus mixed outlook signals from the earnings call (lower revenue guidance and segment declines). These are partially offset by an inexpensive valuation (low P/E and a 3.59% dividend yield) and technically strong but overextended momentum (very high RSI/Stochastic).

To see Spark’s full report on OGN stock, click here.

More about Organon

Organon (NYSE: OGN), based in Jersey City, N.J., operates in the pharmaceuticals sector with a portfolio spanning women’s health, biosimilars and established brands. Key products include contraceptive implant Nexplanon, fertility treatments, respiratory drugs such as Singulair, migraine therapy Emgality, dermatology drug Vtama and a growing biosimilars franchise, positioning the company across both specialty and mature therapeutics markets.

The company reported its fourth-quarter and full-year 2025 results on February 12, 2026, with annual revenue of $6.2 billion, down 3% year on year, and full-year adjusted EBITDA of $1.91 billion, implying a 30.7% margin. Quarterly revenue fell 5% to $1.507 billion, as women’s health, notably Nexplanon, declined on U.S. wholesaler practice changes, policy-driven access limits and softer demand, while biosimilars grew 11% on strong Hadlima and new denosumab and tocilizumab assets.

Established brands slipped modestly as contributions from Emgality, Vtama and Arcoxia were offset by pricing and volume pressure in respiratory drugs, particularly amid revised guidelines that deprioritize montelukast globally. Profitability weakened, with Q4 gross margin dropping to 49.2% from 56.3% and a net loss of $205 million versus prior-year profit, driven by one-time manufacturing optimization costs, unfavorable pricing, FX and product mix, even as management emphasized balance sheet repair and a 2026 outlook broadly in line with 2025 performance.

Average Trading Volume: 5,390,614

Technical Sentiment Signal: Sell

Current Market Cap: $2.03B

See more insights into OGN stock on TipRanks’ Stock Analysis page.